Upgrade to SI Premium - Free Trial

Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Canevari Riccardo

March 31, 2026 6:21 AM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Canevari Riccardo
(Last) (First) (Middle)
SUITE 1 LEVEL 3, 62 LYGON STREET
(Street)
CARLTON SOUTH, VICTORIA 3053
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Managing Director and CEO
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 22,679,986
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) 11/25/2022 11/30/2026 Ordinary Shares 1,225,352 0.2 D
Option (right to buy) 09/13/2024 08/24/2026 Ordinary Shares 1,875,000 0.06 D
Option (right to buy) 11/19/2021 11/25/2026 Ordinary Shares 8,666,678 0.6 D
Option (right to buy) 07/01/2023 06/30/2027 Ordinary Shares 4,167,946 0.17 D
Option (right to buy) 07/01/2024 06/30/2027 Ordinary Shares 4,167,946 0.17 D
Option (right to buy) 07/01/2025 06/30/2027 Ordinary Shares 4,167,946 0.17 D
Option (right to buy) 07/01/2024 07/01/2028 Ordinary Shares 2,475,384 0.112 D
Option (right to buy) 07/01/2025 07/01/2028 Ordinary Shares 2,475,384 0.112 D
Option (right to buy) (1) 07/01/2028 Ordinary Shares 2,476,127 0.112 D
Option (right to buy) 09/13/2024 09/30/2026 Ordinary Shares 12,000,000 0.06 D
Option (right to buy) 07/01/2025 09/30/2026 Ordinary Shares 12,000,000 0.06 D
Option (right to buy) 07/01/2025 06/30/2029 Ordinary Shares 18,416,762 0.041 D
Option (right to buy) (2) 06/30/2029 Ordinary Shares 36,833,524 0.041 D
Option (right to buy) (3) 07/01/2030 Ordinary Shares 74,338,000 0.025 D
Explanation of Responses:
1. Granted on December 01, 2023 and will vest on July 1, 2026 provided Mr. Canevari is still a Director on such dates.
2. Granted on December 16, 2024. 18,416,762 options will vest on July 1, 2026 and 18,416,762 options will vest on July 1, 2027 provided Mr. Canevari is still a Director on such dates.
3. Granted on December 12, 2025. 24,776,855 options will vest on July 1, 2026, 24,776,855 options will vest on July 1, 2027 and 24,784,290 options will vest on July 1, 2028 provided Mr. Canevari is still a Director on such dates.
Remarks:
All exercise prices are in Australian dollars.
/s/ Riccardo Canevari 03/31/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings